ReviewTrends in molecular medicine2011
Cancer microRNAs: from subtype profiling to predictors of response to therapy.
Review in Trends in molecular medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Article
- IsomiR-eQTL: A Cancer-Specific Expression Quantitative Trait Loci Database of miRNAs and Their Isoforms.International journal of molecular sciences · 2022Article
- Article
- Circulating miRNA 27a and miRNA150-5p; a noninvasive approach to endometrial carcinoma.Molecular biology reports · 2021Article
- Identification of a MicroRNA Signature Associated With Lymph Node Metastasis in Endometrial Endometrioid Cancer.Frontiers in genetics · 2021Article
- MiR-93 is related to poor prognosis in pancreatic cancer and promotes tumor progression by targeting microtubule dynamics.Oncogenesis · 2020Article
- MiRNAs: A Powerful Tool in Deciphering Gynecological Malignancies.Frontiers in oncology · 2020Review
- Transcriptomic studies provide insights into the tumor suppressive role of miR-146a-5p in non-small cell lung cancer (NSCLC) cells.RNA biology · 2019Article
- Assessment of the Diagnostic Potential of miR-29a-3p and miR-92a-3p as Circulatory Biomarkers in Acute Myeloid Leukemia.Asian Pacific journal of cancer prevention : APJCP · 2019Article
- Multicellular gene network analysis identifies a macrophage-related gene signature predictive of therapeutic response and prognosis of gliomas.Journal of translational medicine · 2019Article
- Framework for microRNA variant annotation and prioritization using human population and disease datasets.Human mutation · 2019Article
- Mathematical modeling and computational prediction of cancer drug resistance.Briefings in bioinformatics · 2018Review
- Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization.Journal of visualized experiments : JoVE · 2018Article
- miR-222 promotes invasion and migration of ovarian carcinoma by targeting PTEN.Oncology letters · 2018Article
- MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma.Molecular therapy. Nucleic acids · 2017Article
- Inhibition of MicroRNA miR-222 with LNA Inhibitor Can Reduce Cell Proliferation in B Chronic Lymphoblastic Leukemia.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2017Article
- Isoliquiritigenin modulates miR-374a/PTEN/Akt axis to suppress breast cancer tumorigenesis and metastasis.Scientific reports · 2017Article
- The Profile of Serum microRNAs Predicts Prognosis for Resected Gastric Cancer Patients Receiving Platinum-Based Chemotherapy.Digestive diseases and sciences · 2017Article
- A microRNA code for prostate cancer metastasis.Oncogene · 2016Article
- miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway.Cellular oncology (Dordrecht, Netherlands) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
MicroRNAs (miRNAs) are key regulators of gene expression that regulate important oncogenes and tumor suppressors. Many miRNAs can also act as oncogenes or tumor suppressors, and thus the altered expression of miRNAs is a hallmark of many cancer types. Dysregulated miRNAs provide a potentially powerful new tool that could be used to enable the characterization of tumor environments and identify novel and important oncogenic pathways. More recently, there has been growing interest in the field of miRNAs as biomarkers of cancer risk, diagnosis and response to therapy. Understanding the associations between miRNA expression and cancer phenotypes, and the potential of miRNA profiling in clinical applications, promises to be highly rewarding in the field of cancer research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.